Pharmaceutical company Novo Nordisk will expand its production site in Montes Claros, Brazil, creating 600 jobs.

SAO PAULO (Reuters) - Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost production, it said on Monday.

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

(MENAFN- The Rio Times) Novo Nordisk, the Danish pharmaceutical leader, announced a R$6.4 billion ($1.12 billion) investment in its Montes Claros facility in Minas Gerais, Brazil. This expansion ...

Novo Nordisk (NYSE:NVO)) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to supercharge its manufacturing plant in Montes Claros. The goal?

SAO PAULO (Reuters) - Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost production, it said on Monday. The ...